Šestáková Š, Cerovská E, Šálek C, Kundrát D, Ježíšková I, Folta A, Mayer J, Ráčil Z, Cetkovský P, Remešová H: A validation study of petential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel. Clin Epigenetics, 2022, 14, 22.
Poppova L, Pavlova S, Gonzalez B, Kotaskova J, Plevova K, Dumbovic G, Janovska P, Bystry V, Panovska A, Bezdekova L, Maslejova S, Brychtova Y, Doubek M, Krzyzankova M, Borsky M, Mayer J, Bryja V, Alonso S, Pospisilova S: Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene. Epigenetics, 2022, 17, 1628-1635.
Weinbergerová B, Demel I, Víšek B, Válka J, Čerňan M, Jindra P, Novák J, Stejskal L, Kovácsová F, Kabut T, Szotkowski T, Hájek R, Žák P, Cetkovský P, Král Z, Mayer J: Successful Early Use of Anti-SARS-CoV-2 Monoclonal Neutralizing Antibodiesin SARS-Cov-2 Infected Hematological Patients-A Czech Multicenter Experience. Hematol Oncol, 2022, 40, 280-286.
Eckardt JN, Stölzel F, Kunadt D, Röllig C, Stasik S, Wagenführ L, Jöhrens K, Kuithan F, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Shaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Kroschinsky F, Berdel WE, Ehninger G, Serve H, Müler-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Bornhäuser M, Thiede C, Middeke JM: Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. J Hematol Oncol, 2022, 15:60.
Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP: Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia, 2022, 36, 1879-1886.
Šálek C, Folber F, Froňková E, Pecherková P, Jelínková H, Hrabovský Š, Horáček JM, Cetkovský P, Mayer J, Trka J, Doubek M; Czech Leukemia Study Group - for Life (CELL): Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant. Br J Haematol, 2022, 196, 706-710.
Eckardt JN, Stasik S, Röllig C, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Cerqueira T, Kroschinsky F, Berdel WE, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Siepmann T, Bornhäuser M, Middeke JM, Thiede C: Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome. Blood Cancer J, 2023, 13, doi: 10.1038/s41408-023-00790-1.
Valent P, Hartmann K, Bonadonna P, Sperr WR, Niedoszytko M, Hermine O, Kluin-Nelemans HC, Sotlar K, Hoermann G, Nedoszytko B, Broesby-Olsen S, Zanotti R, Lange M, Doubek M, Brockow K, Alvarez-Twose I, Varkonyi J, Yavuz S, Nilsson G, Radia D, Grattan C, Schwaab J, Gülen T, Oude Elberink HNG, Hägglund H, Siebenhaar F, Hadzijusufovic E, Sabato V, Mayer J, Reiter A, Orfao A, Horny HP, Triggiani M, Arock M: European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives. J Allergy Clin Immunol Pract, 2023, 11, 1706-1717.
Weinbergerová B, Čerňan M, Kabut T, Semerád L, Podstavková N, Szotkowski T, Ježíšková I, Mayer J: Gemtuzumab ozogamicin plus midostaurin in conjuction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients-Czech Center experience. Haematol, 2023, 108, 2826-9.
Eckardt JN, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi JA, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, Krug U, Braess J, Görlich D, Sauerland C, Woermann B, Herold T, Hiddemann W, Müller-Tidow C, Serve H, Baldus CD, Schäfer-Eckart K, Kaufmann M, Krause SW, Hänel M, Berdel WE, Schliemann C, Mayer J, Hanoun M, Schetelig J, Wendt K, Bornhäuser M, Thiede C, Middeke JM: Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med, 2023, 3:68, doi: 10.1038/s43856-023-00298-6.
Eckardt JN, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Oelschlägel U, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhäuser M, Middeke JM, Thiede C: Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia. Leukemia, 2023, 37, 2395-2403.
Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M: The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia, 2024, 38, 318-325.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Cengiz Seval G, Weinbergerová B, Bonuomo V, Bilgin YM, van Doesum J, Jaksic O, Víšek B, Falces-Romero I, Marchetti M, Dávila-Valls J, Martín-Pérez S, Nucci M, López-García A, Itri F, Buquicchio C, Verga L, Piukovics K, Navrátil M, Collins GP, Jiménez M, Fracchiolla NS, Labrador J, Prezioso L, Rossi E, Čolović N, Meers S, Kulasekararaj A, Cuccaro A, Blennow O, Valković T, Sili U, Ledoux MP, Batinić J, Passamonti F, Machado M, Duarte RF, Poulsen CB, Méndez GA, Espigado I, Demirkan F, Čerňan M, Cattaneo C, Petzer V, Magliano G, Garcia-Vidal C, El-Ashwah S, Gomes-Da-Silva M, Vena A, Ormazabal-Vélez I, van Praet J, Dargenio M, De-Ramón C, Del Principe MI, Marques-De-Almeida J, Wolf D, Szotkowski T, Obr A, Çolak GM, Nordlander A, Izuzquiza M, Cabirta A, Zambrotta GPM, Cordoba R, Žák P, Ammatuna E, Mayer J, Ilhan O, García-Sanz R, Quattrone M, Arellano E, Nunes-Rodrigues R, Emarah Z, Aiello TF, Hanakova M, Ráčil Z, Bavastro M, Limongelli A, Rahimli L, Marchesi F, Cornely OA, Pagano L: Survival in multiple myeloma and SARS-COV-2 infection trough the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol, 2024, 42, e:3240.
Šestáková Š, Šálek C, Kundrát D, Cerovská E, Vydra J, Ježíšková I, Folta A, Mayer J, Cetkovský P, Remešová H: MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia. Clin Epigenetics, 2024, 16(1):17.
Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D: De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tarosine kinase inhibitors. An J Hematol, 2024, 763-766..
Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, Mayer J:Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia, 2024, 38, 893-897.
Salmanton-García J, Marchesi F, Farina F, Weinbergerová B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DS, Gomes da Silva M, Nunes Rodrigues R, López-García A, Córdoba R, Bilgin YM, Falces-Romero I, El-Ashwah S, Emarah Z, Besson C, Kohn M, Van Doesum J, Ammatuna E, Marchetti M, Labrador J, Zambrotta GPM, Verga L, Jaksic O, Nucci M, Piukovics K, Cabirta-Touzón A, Jiménez M, Arellano E, Espigado I, Blennow O, Nordlander A, Meers S, van Praet J, Aiello TF, Garcia-Vidal C, Fracchiolla N, Sciumè M, Seval GC, Žák P, Buquicchio C, Tascini C, Gräfe SK, Schönlein M, Adžić-Vukičević T, Bonuomo V, Cattaneo C, Nizamuddin S, Čerňan M, Plantefeve G, Prin R, Szotkovski T, Collins GP, Dargenio M, Petzer V, Wolf D, Čolović N, Prezioso L, Valković T, Passamonti F, Méndez GA, Sili U, Vena A, Bavastro M, Limongelli A, Duarte RF, Ledoux MP, Cvetanoski M, Stojanoski Z, Machado M, Batinić J, Magliano G, Biernat MM, Pantić N, Poulsen CB, Cuccaro A, Del Principe MI, Kulasekararaj A, Ormazabal-Vélez I, Busca A, Demirkan F, Ijaz M, Klimko N, Stoma I, Khostelidi S, Fernández N, Omrani AS, Bergantim R, De Jonge N, Fouquet G, Navrátil M, Abu-Zeinah G, Samarkos M, Maertens J, De Ramón C, Guidetti…: Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. eClinicalMedicine, 2024, 71, 102553.
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M: Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era-analysis of the European LeukemiaNet Blast Phase Registry. Leukemia, 2024, 38, 1072-1080.
Perusini MA, Žáčková D, Kim T, Pagnano K, Pavlovsky C, Ježíšková I, Kvetková A, Jurček T, Kim J, Yoo Y, Yi S, Lee H, Kim KH, Chang M, Capo-Chichi JM, Medeiros JJF, Arruda A, Minden M, Zhang Z, Abelson S, Mayer J, Hwan Kim DD: Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood Adv, 2024, 8, 2361-2372.
Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators: The european stop tyrosine kinase inhibitor trial (euro-ski) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol, 2024, 42, 1875-1880.
Weinbergerová B, Mayer J, Kabut T, Sperr WR, Števková J, Jonášová A, Čerňan M, Herndlhofer S, Oravcová I, Šrámek J, Novák J, Štěpánová R, Szotkowski T, Drgoňa L, Žák P, Valent P: Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis. Br J Haematol, 2024, 205, 1746-1750.
Belohlavkova P, Zackova D, Klamova H, Faber E, Karas M, Stejskal L, Cmunt E, Cerna O, Jeziskova I, Machova Polakova K, Zak P, Jurkova T, Chrapava M, Mayer J: Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid -Nationwide real life data. Cancer Med, 2024, 13, e70158.
Efficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M, Nicolini FE, Mayer J, Zackova D, Janssen JJWM, Panayiotidis P, Vestergaard H, Koskenvesa P, Almeida A, Hjorth-Hansen H, Martinez-Lopez J, Olsson-Strömberg U, Hochhaus A, Berger MG, Etienne G, Klamova H, Faber E, Rousselot P, Pfirrmann M, Saussele S: Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia, 2024, 38, 1722-1730.
Sobas MA, Turki AT, Ramiro AV, Hernández-Sánchez A, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L: Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Haematologica, 2024, in print.
Salmanton-García J, Marchesi F, Navrátil M, Piukovics K, Del Principe MI, Criscuolo M, Bilgin YM, Fracchiolla NS, Vena A, Romano A, Falces-Romero I, Sgherza N, Heras-Fernando I, Biernat MM, Petzer V, Žák P, Weinbergerová B, Samarkos M, Erben N, van Praet J, López-García A, Labrador J, Lahmer T, Drgoňa Ľ, Merelli M, Cuccaro A, Martín-Pérez S, Dávila-Valls J, Farina F, Cattaneo C, Pinczés LI, Magyari F, Espigado I, Buquicchio C, Vinh DC, Stoma I, Čerňan M, Prezioso L, Papa MV, Plantefeve G, Khedr RA, Batinić J, Magliano G, Erdem S, Khostelidi S, Čolović N, Nappi D, García-Ramírez P, Góra J, Callejas-Charavia M, Tłusty J, Bakker M, Wojtyniak E, Antić D, Magdziak A, Dargenio M, Idrizović L, Pantić N, Stojanoski Z, Eisa N, Otašević V, Marchetti M, Mackenzie E, Garcia-Vidal C, Aujayeb A, Almasari A, Miranda-Castillo C, Gavriilaki E, Coppola N, Busca A, Adžić-Vukičević T, Schönlein M, Hersby DS, Gräfe SK, Glenthøj A, Aiello TF, Cvetanoski M, Mitrović M, Cerchione C, Prin R, Varricchio G, Arellano E, Córdoba R, Mayer J, Víšek B, Wolf D, Anastasopoulou AN, Delia M, Musto P, Leotta D, Bavastro M, Limongelli A, Sciumè M, van den Ven L, Fianchi L, Brunetti SC, Drozd-Sokołowska J at all: Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA – EPIFLUEHA Report. Am J Hematol, 2024, in print.
Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M: Single or Double Induction With 7+3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. J Clin Oncol, 2025, 43, 65-74.
Clinical and prognostic signifikance of additional chromosomal abnormalities at diagnosis of chronic myeloid leukemia. Am J Hematol, 2025 in print, available on line.
Folber F., Koriťáková E. Portál české leukemické skupiny [online]. 2016 [cit. 2025-5-01].
Dostupné z: http://www.leukemia-cell.org.
2025 CELL - the Czech leukemia study group for life | site map